$TAK

Global stem cell therapy market projected to grow from $21.9B in 2025 to $58.5B by 2034 at 11% CAGR, driven by technological advances and favorable regulations.

IgA Nephropathy market projects 18.6% CAGR through 2036 from $1.5B base, driven by novel immunotherapies and recent FDA approvals reshaping kidney disease treatment.

Polycythemia vera market expected to expand 8.9% CAGR through 2036 from $2B base as nine pharma companies advance novel therapies, with rusfertide entering first.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.

Over 90 pharmaceutical companies are advancing 100+ psoriasis drugs through clinical trials, with major players like Takeda and Alumis posting positive Phase III results.

US eosinophilic esophagitis market valued at $647M in 2025 projected to grow 13.2% annually through 2036, driven by novel drug classes and improved diagnostics.

Crohn's Disease drug market projected to grow 45% to $13.8B by 2032, driven by eight new therapies with novel mechanisms of action reshaping competition.

Takeda exits dementia drug partnership with Denali Therapeutics on DNL593. Denali regains full control, plans Phase 1/2 data release by end-2026. Denali shares fell 3.73%.

Eli Lilly announces $3B China investment and Mounjaro reimbursement win, but faces multibillion-dollar lawsuit over Actos disclosures.

Feiba VH market projected to grow through 2035 driven by rising hemophilia diagnoses, healthcare spending, and surgical procedures. North America leads; Asia-Pacific fastest-growing.

Takeda stock fell 0.64% despite positive Phase 3 results for Entyvio in pediatric ulcerative colitis, with 47.3% of patients achieving clinical remission.

Blood plasma derivatives market to double to $104B by 2033, driven by rising disease prevalence and immunoglobulin demand across developed and emerging markets.

FDA grants J&J's Rybrevant Faspro breakthrough designation for HPV-negative head and neck cancer, potentially accelerating patient access to this new treatment option.